Generic Ketamine Tablets vs Brand-Name Products

There is no FDA-approved oral ketamine tablet for depression, pain, or other psychiatric use. Every oral ketamine tablet prescribed today comes from a compounding pharmacy rather than a large-scale pharmaceutical manufacturer. Understanding ketamine generic and brand name differences matters because it shapes what a patient can expect on quality control, cost, and where treatment is actually available.

The only FDA-approved ketamine-based products on the market are Ketalar, an injectable anesthetic, and Spravato, an esketamine nasal spray for treatment-resistant depression. Neither is an oral tablet. This guide compares what compounded generic tablets offer today against the brand-name products currently in development.

The Current Landscape

Generic Compounded Ketamine Tablets

Most ketamine tablets used in clinical practice today come from compounding pharmacies, which fall into two regulatory categories. 503A pharmacies prepare medications for individual patients under a specific prescription and are primarily overseen by state boards of pharmacy. 503B outsourcing facilities produce medications in larger batches and must register with the FDA and follow current good manufacturing practices (cGMP), the same quality standards required of pharmaceutical manufacturers. According to the FDA, this distinction is central to how compounded drugs are regulated, since 503A pharmacies are not required to meet full cGMP standards the way 503B facilities are.

Compounded ketamine tablets and troches use the same active ingredient, racemic ketamine hydrochloride, found in the FDA-approved injectable formulation. The difference is the dosage form: a compounding pharmacy, not a regulated pharmaceutical manufacturer, creates the tablet or troche.

Brand-Name Products

Ketalar is the only FDA-approved ketamine product on the market. It is an injectable formulation approved for anesthesia, not an oral tablet. Spravato is an FDA-approved nasal spray containing esketamine, the S-enantiomer, or mirror-image molecule, of ketamine; it is approved for treatment-resistant depression but is not a tablet and delivers only one enantiomer rather than the racemic mixture used in compounded tablets. Several pharmaceutical companies are pursuing FDA approval for proprietary oral ketamine formulations. Clexio Biosciences has an extended-release ketamine tablet reported to be in Phase 2/3 trials, though no oral ketamine product has completed FDA review for psychiatric use as of this writing.

Key Comparisons

Quality Control

Compounded generic quality varies by pharmacy. PCAB, the Pharmacy Compounding Accreditation Board, accredits compounding pharmacies that meet specific quality and safety standards, and facilities with PCAB accreditation or 503B status generally provide more consistent testing and documentation. Poorly managed pharmacies carry a higher risk of inconsistent potency or contamination, and the FDA has issued warning letters to specific compounding pharmacies over quality violations. Brand-name products, once approved, are manufactured under cGMP with batch testing and stability data, so each unit contains a verified amount of active ingredient. That consistency is the main advantage brand-name manufacturing offers over compounding.

Cost and Availability

Compounded generic tablets typically cost $8 to $30 per dose and are rarely covered by insurance, but they are widely available now through any compounding pharmacy authorized to handle controlled substances. When a proprietary oral ketamine product reaches market, industry pricing precedent, including Spravato, suggests a per-dose cost of roughly $50 to $200 or more, though insurance coverage would likely offset that cost for insured patients. No brand-name oral product for psychiatric use is available today, and future distribution could be restricted through a REMS program, a Risk Evaluation and Mitigation Strategy the FDA requires for certain higher-risk drugs, similar to the one that governs Spravato.

Formulation Flexibility

Compounding allows a prescriber to request a specific dose, formulation such as tablet, troche, capsule, or solution, and combination for an individual patient. Brand-name products come in fixed doses with less flexibility but more standardization. Extended-release formulations in development may offer pharmacokinetic advantages, such as smoother plasma levels and fewer side effects, that current compounded immediate-release tablets cannot replicate.

What the Future May Hold

If a pharmaceutical company secures FDA approval for an oral ketamine tablet, the landscape could shift in several ways: standardized quality and dosing, wider insurance coverage, and possibly a REMS program governing how the drug is prescribed and dispensed. Compounded generics would likely remain available, but they could face additional regulatory scrutiny once a competing approved product enters the market. Final pricing will depend on competition among manufacturers and how insurers negotiate coverage.

For now, compounded generic ketamine tablets remain the standard of care for oral ketamine therapy, and they can provide effective treatment when sourced from a reputable, accredited pharmacy.

References

• FDA: Human Drug Compounding, covering 503A and 503B distinctions and quality standards.
• PubChem: Ketamine Compound Summary, NCBI's chemical database entry with molecular data and pharmacokinetics.
• StatPearls: Ketamine, a clinical reference on ketamine pharmacology and mechanisms of action, available through the NCBI Bookshelf.
• MedlinePlus: Ketamine Injection, National Library of Medicine consumer drug information on uses and precautions.